Ernexa Therapeutics (ERNAW) Cash & Equivalents (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Cash & Equivalents data on file, last reported at $9.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 378.47% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 378.47% YoY) and the FY2025 annual result came in at $1.9 million, up 8.96% from the prior year.
• Cash & Equivalents advanced to $9.2 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $23.5 million in Q1 2022 to a low of $1.7 million in Q4 2024.
• A 5-year average of $8.8 million and a median of $8.6 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 85.18% — and 2026, when it soared 378.47%.
• Tracing ERNAW's Cash & Equivalents over 5 years: stood at $15.5 million in 2022, then fell by 24.91% to $11.7 million in 2023, then slumped by 85.18% to $1.7 million in 2024, then grew by 8.96% to $1.9 million in 2025, then soared by 387.1% to $9.2 million in 2026.
• The last three Cash & Equivalents figures came in at $9.2 million (Q1 2026), $1.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.